News

Suzhou, April 21, 2025 – WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), and Delonix Bioworks, a global pioneer in innovative bacterial vaccine development, today announced a strategic partnership. Through the collaboration, Delonix Bioworks will leverage WuXi Vaccines’ integrated development and manufacturing capabilities as well as the world-class quality system to advance OMV Plus, Delonix Bioworks’ next-generation Outer Membrane Vesicle (OMV) technology platform, driving its widespread adoption for bacterial vaccines. Together, the companies will jointly facilitate innovation in bacterial vaccines, contributing to the protection of public health worldwide.

Antimicrobial resistance has been designated as one of the top ten global public health threats by the World Health Organization (WHO). In the post-antibiotic era, development and application of more bacterial vaccines can help prevent population- and healthcare-associated infections with multidrug-resistant (MDR) microbes, and minimize antimicrobial use and resistance.

Among the most promising next-generation bacterial vaccines, engineered OMV vaccines effectively address the technical challenges in the complex screening of optimal antigens. They provide a built-in adjuvant effect that enhances vaccine potency without requiring additional adjuvants, and their commercial applications have been validated in the market. Delonix Bioworks’ OMV Plus platform has successfully overcome the key technical bottlenecks of traditional OMV vaccines, significantly increasing both yield and coverage, and enabling the development of vaccines against the majority of gram-negative bacteria.

In 2024, WuXi Vaccines and Delonix Bioworks entered into a collaboration that successfully achieved GMP-scale production of engineered OMV vaccines within 10 months. The production yield exceeded 1 million doses per 100L fermentation batch, with manufacturing costs below $1 per dose. This achievement established a solid foundation for expanding the strategic partnership between the two companies.

Dr. Qiubin Lin, founder and CEO of Delonix Bioworks, commented, “We are delighted to announce the strategic partnership with WuXi Vaccines, aimed at accelerating global access to novel bacterial vaccine technologies. After a year of intensive collaboration, marked by dedicated efforts and innovative approaches from both teams, we have combined Delonix Bioworks’ robust vaccine innovation capabilities with WuXi Vaccines’ in-depth know-how and expertise in vaccine CMC and manufacturing to achieve a landmark milestone – successfully scaling up the production of China’s first MenB OMV vaccine at an unprecedented pace. This partnership not only enables significant improvements in productivity and manufacturing cost reduction, but also underscores Delonix Bioworks’ global leadership in pathogen genome capabilities and our shared commitment to enhancing the accessibility of novel bacterial vaccines.”

Mr. Jian Dong, CEO of WuXi Vaccines, commented, “We sincerely appreciate Delonix Bioworks’ longstanding trust in us. This strategic collaboration reaffirms WuXi Vaccines’ value in expediting innovative vaccine development through our integrated platforms that uphold the utmost quality standards. Through this collaboration, both parties will fully leverage our combined strengths in OMV vaccine R&D, process development, and large-scale manufacturing to accelerate the research and commercialization of innovative bacterial vaccines for a broader range of global partners. WuXi Vaccines remains committed to meeting the growing demand for vaccine development and manufacturing services with our profound expertise and comprehensive end-to-end solutions, thereby improving the accessibility and affordability of vaccines worldwide to protect public health.”

About WuXi Vaccines

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine and preventive antibody development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners’ vaccines and preventive antibodies to the clinical stage and the market, regardless of the modality (recombinant protein, viral, viral vectored, VLP, OMV, nucleic acid, or conjugated vaccines). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (cell culture, viral, microbial, polysaccharide and protein conjugation), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine development to large-scale commercial production and distribution. The company can enable global clients to deliver critical vaccines and preventive antibodies anywhere in the world, making it an essential partner in protecting public health. For more information about WuXi Vaccines, please visit: https://wuxivaccines.com.

About Delonix Bioworks

Delonix Bioworks is a leading biotech pioneering innovative bacterial vaccine development, transforming the field from empirical approaches to rational design.

Founded by pioneers in synthetic biology and vaccinology, we have developed comprehensive genome editing toolkits for over 15 pathogens and established multiple proprietary vaccine technology platforms. Our flagship OMV Plus platform is a state-of-the-art genetically engineered technology that produces OMV vaccine candidates with enhanced efficacy and safety profiles. It enables scalable, cost-effective production and significantly accelerates the development timeline. This platform powers our Meningococcal Group B vaccine candidate, which shows best-in-class profiles and is approaching IND submission in 2025.

Delonix Bioworks has won multiple awards in China and globally, including the Champion in Boehringer Ingelheim Innovation Prize. For more information, please visit https://delonixbio.com/.

Contacts

Business

WuXiVaccines@wuxibiologics.com

Media

PR@wuxibiologics.com